Friday, 15 Feb 2019

You are here

Immunophysiology of the Gout Attack

Gout may be an ancient disease, with arthritis of the big toe having been described in Egypt in 2,600 BC, but only now are the underlying pathophysiologic events being elucidated and understood.

Current thinking on the pathogenesis of gout, which today affects more than 8 million Americans -- 4% of the population -- has evolved into the "mobilization flare" hypothesis. In this disease conceptualization, when serum urate levels exceed 6 mg/dL, even in asymptomatic individuals, deposition of urate crystals in the synovium and other tissues begins.

"Gout represents the most hyperinflamed situation we know about," said Peter Lipsky, MD, from Charlottesville, Virginia, at the Florida Society of Rheumatology annual meeting.

Crystals of monosodium urate form in close proximity to each other and proteins and rapidly become an insoluble crystalline lattice structure, explained Lipsky, the former scientific director of NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases in Bethesda, Maryland.

The surface of that structure is quite active and is in equilibrium with uric acid levels in surrounding tissues. But with sudden changes in the microenvironment, which could be the level of uric acid, pH, temperature, or changes in proteins that increase their solubility, the lattice matrix becomes unstable and crystals begin to shed off the surface into the surrounding tissue, he noted.

"If the shedding is relatively modest, with only a few crystals being released, those can be opsonized with a variety of positively charged proteins including ApoE and they do not become inflammatory," he said.

However, if a large mass of crystals is shed, the crystals can begin to interact with receptors on immune cells, the process of inflammation begins, and if the crystals are opsonized with immunoglobulin, the process is further heightened.

"It's a very dynamic process occurring at the surface of this crystalline lattice structure, and it's the additional proteins in the environment that seem to control whether or not the crystals are shed," he noted.

Further understanding of the underlying processing leading to gout derived from work initially done at the NIH among children with autoinflammatory diseases, in which a cellular structure known as the inflammasome was described, according to Lipsky.

The NLRP3 inflammasome is capable of sensing the presence of a variety of intracellular molecules and can lead to the induction of inflammatory responses. When the molecule is the monosodium urate crystal and not soluble monosodium urate, the multiprotein structure assembles and releases activated caspase-1, which is the critical enzyme involved in the processing of interleukins (IL) 1 and 18 and other proinflammatory molecules. This leads to the production and release from the cell of active IL-1 and IL-18 -- and the inflammatory response.

"This is the basis of how we now understand that urate crystals stimulate inflammation, and is also the basis of why the IL-1 blocker canakinumab [Ilaris] seems to be so effective in controlling inflammation in gout," he concluded.

Dr. Lipsky disclosed a relevant relationships with Horizon Pharma.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

U.S. Gout Rates Remain Steady, but Substantial

Using data from 5,467 adults in the US in the National Health and Nutrition Examination Survey (NHANES) for the years 2007-2016, researchers found that the prevalence of gout and hyperuricemia has remained at 3.9%, having doubled from the 1960s to the 1990s, corresponding to an estimated 9.2 million adults with gout in 2015-2016.

Febuxostat Gets Reprieve from FDA Advisory Panel

On January 11, 2019 the FDA convened two advisory panels (the Arthritis Advisory Committee [AAC] and the Drug Safety and Risk Management Advisory Committee [DSaRM]) to consider the cardiovascular safety of febuxostat (Uloric) based on the 2018 “Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) study. 

The Vote

Only One-Third of Gout Patients Receive Urate-Lowering Drugs

The most recent analysis of National Health and Nutrition Examination Survey [NHANES] 2007-2016) data shows the prevalence of gout to be 9.3 million in the USA.

Data from 5,467 participants from NHANES 2015-2016, finds gout in 3.9% or  9.2 million US adults.  This includes 5.2% [5.9 million] of men and 2.7% [3.3 million] of  women with gout.

Sleep Apnea Increases Gout Risk

Both Gout and obstructive sleep apnea (OSA) comingle with a wide range of serious comorbidities. A matched retrospective cohort study from the UK Clinical Practice Research database shows those with OSA are at a higher risk of developing gout.

This report compared 15,879 patients with OSA versus 63,296 without; median follow‐up was 5.8 years.

Hepatic Safety of Urate Lowering Therapies in Gout

Lee and a group of Korean investigators have analyzed the comparative safety of allopurinol and febuxostat in a small cohort of gout patients with fatty liver disease (FLD) and found febuxostat had a lower risk for hepatotoxicity (defined as AST or ALT at least 3× the upper limit of normal) compared to allopurinol.